

CLAIMS AFTER AMENDMENT**In the Claims:**

1-59 Cancelled.

- 60.<sup>1</sup> (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 353 nucleotides.
- 61.<sup>2</sup> (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 586 nucleotides.
- 62.<sup>3</sup> (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lamda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 353 nucleotides.
- 63.<sup>4</sup> (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lamda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 586 nucleotides.

- <sup>5</sup>  
64. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 353 nucleotides.
- <sup>6</sup>  
65. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 586 nucleotides.
- <sup>7</sup>  
66. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 353 nucleotides.
- <sup>8</sup>  
67. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 586 nucleotides.
- <sup>9</sup>  
68. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figures 57, wherein said polynucleotide has a maximum length of 353 nucleotides.
- <sup>10</sup>  
69. (Previously Presented) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the

nucleotide sequence in Figure 57, wherein said polynucleotide has a maximum length of 586 nucleotides.

70.<sup>11</sup> (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

71.<sup>12</sup> (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

72.<sup>13</sup> (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

73.<sup>14</sup> (Previously Amended) A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 8 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

74.<sup>15</sup> (Previously Presented) A polynucleotide according to any one of claims ~~60-73~~<sup>1-14</sup>, wherein said contiguous sequence is at least 10 nucleotides.

- 67  
75. (Previously Presented) A polynucleotide according to any one of claims ~~60-73~~<sup>1-14</sup>, wherein said contiguous sequence is at least 12 nucleotides.
- 119  
76. (Previously Presented) A polynucleotide according to any one of claims ~~60-73~~<sup>1-14</sup>, wherein said contiguous sequence is at least 15 nucleotides.
- 170  
77. (Previously Presented) A polynucleotide according to any one of claims ~~60-73~~<sup>1-14</sup>, wherein said contiguous sequence is at least 20 nucleotides.
- 222  
78. (Previously Presented) A polynucleotide according to any of claims ~~60-73~~<sup>1-14</sup> wherein said polynucleotide has a maximum length of 161 nucleotides.
- 16  
79. (Previously Presented) A polynucleotide according to claim ~~74~~<sup>15</sup> wherein said polynucleotide has a maximum length of 161 nucleotides.
- 68  
80. (Previously Presented) A polynucleotide according to claim ~~75~~<sup>67</sup> wherein said polynucleotide has a maximum length of 161 nucleotides.
- 120  
81. (Previously Presented) A polynucleotide according to claim ~~76~~<sup>119</sup> wherein said polynucleotide has a maximum length of 161 nucleotides.
- 171  
82. (Previously Presented) A polynucleotide according to claim ~~77~~<sup>170</sup> wherein said polynucleotide has a maximum length of 161 nucleotides.
- 239  
83. (Previously Presented) A polynucleotide according to any of claims ~~60-73~~<sup>1-14</sup> wherein said polynucleotide has a maximum length of 108 nucleotides.
- 33  
84. (Previously Presented) A polynucleotide according to claim ~~74~~<sup>15</sup> wherein said polynucleotide has a maximum length of 108 nucleotides.

- 86  
85. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide has a maximum length of 108 nucleotides.
- 137 119  
86. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 108 nucleotides.
- 188 170  
87. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 108 nucleotides
- 257 1-14  
88. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is single stranded.
- 51 15  
89. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is single stranded.
- 103 67  
90. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is single stranded.
- 154 119  
91. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is single stranded.
- 204 170  
92. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is single stranded.
- 273 222  
93. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is single stranded.
- 17 16  
94. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is single stranded.

- 69  
95. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is single stranded.
- 121  
96. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is single stranded.
- 172  
97. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is single stranded.
- 240  
98. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is single stranded.
- 34  
99. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is single stranded.
- 87  
100. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is single stranded.
- 138  
101. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is single stranded.
- 189  
102. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is single stranded.
- 265  
103. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is DNA.
- 58  
104. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is DNA.

- 110  
105. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is DNA.
- 161  
106. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is DNA.
- 213  
107. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is DNA.
- 230  
108. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is DNA.
- 24  
109. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is DNA.
- 77  
110. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is DNA.
- 128  
111. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is DNA.
- 179  
112. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is DNA.
- 247  
113. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is DNA.
- 42  
114. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is DNA.

- 94  
115. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is DNA.
- 145  
116. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is DNA.
- 197  
117. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is DNA.
- 258  
118. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is DNA.
- 52  
119. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is DNA.
- 104  
120. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is DNA.
- 155  
121. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is DNA.
- 207  
122. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is DNA.
- 224  
123. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is DNA.
- 18  
124. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is DNA.



- 70  
125. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is DNA. 69
- 122  
126. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is DNA. 121
- 173  
127. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is DNA. 172
- 241  
128. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is DNA. 240
- 35  
129. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is DNA. 34
- 88  
130. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is DNA. 87
- 139  
131. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is DNA. 138
- 190  
132. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is DNA. 189
- 267  
133. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is labeled. 1-14
- 60  
134. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is labeled. 15

112  
135. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is labeled.

163  
136. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is labeled.

215  
137. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is labeled.

232  
138. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is labeled.

26  
139. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is labeled.

79  
140. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is labeled.

130  
141. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is labeled.

181  
142. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is labeled.

247  
143. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is labeled.

44  
144. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is labeled.

96  
145. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is labeled.

147  
146. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is labeled.

199  
147. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is labeled.

260  
148. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is labeled.

54  
149. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is labeled.

106  
150. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is labeled.

157  
151. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is labeled.

209  
152. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is labeled.

226  
153. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is labeled.

20  
154. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is labeled.

72 69  
155. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is labeled.

124 121  
156. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is labeled.

175 172  
157. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is labeled.

243 240  
158. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is labeled.

37 34  
159. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is labeled.

90 87  
160. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is labeled.

141 138  
161. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is labeled.

192 189  
162. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is labeled.

266 265  
163. (Previously Presented) A polynucleotide according to claim 103 wherein said polynucleotide is labeled.

59 58  
164. (Previously Presented) A polynucleotide according to claim 104 wherein said polynucleotide is labeled.

111  
165. (Previously Presented) A polynucleotide according to claim 105 wherein said polynucleotide is labeled.

162  
166. (Previously Presented) A polynucleotide according to claim 106 wherein said polynucleotide is labeled.

214  
167. (Previously Presented) A polynucleotide according to claim 107 wherein said polynucleotide is labeled.

231  
168. (Previously Presented) A polynucleotide according to claim 108 wherein said polynucleotide is labeled.

25  
169. (Previously Presented) A polynucleotide according to claim 109 wherein said polynucleotide is labeled.

78  
170. (Previously Presented) A polynucleotide according to claim 110 wherein said polynucleotide is labeled.

129  
171. (Previously Presented) A polynucleotide according to claim 111 wherein said polynucleotide is labeled.

190  
172. (Previously Presented) A polynucleotide according to claim 112 wherein said polynucleotide is labeled.

248  
173. (Previously Presented) A polynucleotide according to claim 113 wherein said polynucleotide is labeled.

43  
174. (Previously Presented) A polynucleotide according to claim 114 wherein said polynucleotide is labeled.

- 95  
175. (Previously Presented) A polynucleotide according to claim 115 wherein said polynucleotide is labeled.
- 146  
176. (Previously Presented) A polynucleotide according to claim 116 wherein said polynucleotide is labeled.
- 198  
177. (Previously Presented) A polynucleotide according to claim 117 wherein said polynucleotide is labeled.
- 259  
178. (Previously Presented) A polynucleotide according to claim 118 wherein said polynucleotide is labeled.
- 53  
179. (Previously Presented) A polynucleotide according to claim 119 wherein said polynucleotide is labeled.
- 105  
180. (Previously Presented) A polynucleotide according to claim 120 wherein said polynucleotide is labeled.
- 156  
181. (Previously Presented) A polynucleotide according to claim 121 wherein said polynucleotide is labeled.
- 208  
182. (Previously Presented) A polynucleotide according to claim 122 wherein said polynucleotide is labeled.
- 225  
183. (Previously Presented) A polynucleotide according to claim 123 wherein said polynucleotide is labeled.
- 19  
184. (Previously Presented) A polynucleotide according to claim 124 wherein said polynucleotide is labeled.

185. (Previously Presented) A polynucleotide according to claim <sup>71</sup>125 wherein said polynucleotide is labeled. <sup>70</sup>
186. (Previously Presented) A polynucleotide according to claim <sup>123</sup>126 wherein said polynucleotide is labeled. <sup>122</sup>
187. (Previously Presented) A polynucleotide according to claim <sup>174</sup>127 wherein said polynucleotide is labeled. <sup>173</sup>
188. (Previously Presented) A polynucleotide according to claim <sup>242</sup>128 wherein said polynucleotide is labeled. <sup>241</sup>
189. (Previously Presented) A polynucleotide according to claim <sup>36</sup>129 wherein said polynucleotide is labeled. <sup>35</sup>
190. (Previously Presented) A polynucleotide according to claim <sup>89</sup>130 wherein said polynucleotide is labeled. <sup>88</sup>
191. (Previously Presented) A polynucleotide according to claim <sup>140</sup>131 wherein said polynucleotide is labeled. <sup>139</sup>
192. (Previously Presented) A polynucleotide according to claim <sup>191</sup>132 wherein said polynucleotide is labeled. <sup>190</sup>
193. (Previously Presented) A polynucleotide according to any of claims <sup>269</sup>60-73 wherein said polynucleotide is RNA. <sup>1-14</sup>
194. (Previously Presented) A polynucleotide according to claim <sup>61</sup>74 wherein said polynucleotide is RNA. <sup>15</sup>

- 113 67  
195. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is RNA.
- 164 119  
196. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is RNA.
- 216 170  
197. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is RNA.
- 233 222  
198. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is RNA.
- 27 16  
199. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is RNA.
- 80 68  
200. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is RNA.
- 131 120  
201. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is RNA.
- 182 171  
202. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is RNA.
- 251 239  
203. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is RNA.
- 45 33  
204. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is RNA.



- 97  
205. (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is RNA.
- 148  
206. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is RNA.
- 200  
207. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is RNA.
- 261  
208. (Previously Presented) A polynucleotide according to claim 88 wherein said polynucleotide is RNA.
- 55  
209. (Previously Presented) A polynucleotide according to claim 89 wherein said polynucleotide is RNA.
- 107  
210. (Previously Presented) A polynucleotide according to claim 90 wherein said polynucleotide is RNA.
- 158  
211. (Previously Presented) A polynucleotide according to claim 91 wherein said polynucleotide is RNA.
- 210  
212. (Previously Presented) A polynucleotide according to claim 92 wherein said polynucleotide is RNA.
- 227  
213. (Previously Presented) A polynucleotide according to claim 93 wherein said polynucleotide is RNA.
- 21  
214. (Previously Presented) A polynucleotide according to claim 94 wherein said polynucleotide is RNA.

- 73  
215. (Previously Presented) A polynucleotide according to claim 95 wherein said polynucleotide is RNA. 69
- 125  
216. (Previously Presented) A polynucleotide according to claim 96 wherein said polynucleotide is RNA. 121
- 176  
217. (Previously Presented) A polynucleotide according to claim 97 wherein said polynucleotide is RNA. 172
- 244  
218. (Previously Presented) A polynucleotide according to claim 98 wherein said polynucleotide is RNA. 240
- 38  
219. (Previously Presented) A polynucleotide according to claim 99 wherein said polynucleotide is RNA. 34
- 91  
220. (Previously Presented) A polynucleotide according to claim 100 wherein said polynucleotide is RNA. 87
- 142  
221. (Previously Presented) A polynucleotide according to claim 101 wherein said polynucleotide is RNA. 138
- 193  
222. (Previously Presented) A polynucleotide according to claim 102 wherein said polynucleotide is RNA. 159
- 270  
223. (Previously Presented) A polynucleotide according to claim 193 wherein said polynucleotide is labeled. 269
- 62  
224. (Previously Presented) A polynucleotide according to claim 194 wherein said polynucleotide is labeled. 61

- 114  
225. (Previously Presented) A polynucleotide according to claim 195 wherein said polynucleotide is labeled.
- 165  
226. (Previously Presented) A polynucleotide according to claim 196 wherein said polynucleotide is labeled.
- 217  
227. (Previously Presented) A polynucleotide according to claim 197 wherein said polynucleotide is labeled.
- 234  
228. (Previously Presented) A polynucleotide according to claim 198 wherein said polynucleotide is labeled.
- 28  
229. (Previously Presented) A polynucleotide according to claim 199 wherein said polynucleotide is labeled.
- 81  
230. (Previously Presented) A polynucleotide according to claim 200 wherein said polynucleotide is labeled.
- 132  
231. (Previously Presented) A polynucleotide according to claim 201 wherein said polynucleotide is labeled.
- 183  
232. (Previously Presented) A polynucleotide according to claim 202 wherein said polynucleotide is labeled.
- 252  
233. (Previously Presented) A polynucleotide according to claim 203 wherein said polynucleotide is labeled.
- 46  
234. (Previously Presented) A polynucleotide according to claim 204 wherein said polynucleotide is labeled.

- 98  
235. (Previously Presented) A polynucleotide according to claim 205 wherein said polynucleotide is labeled.
- 149  
236. (Previously Presented) A polynucleotide according to claim 206 wherein said polynucleotide is labeled.
- 201  
237. (Previously Presented) A polynucleotide according to claim 207 wherein said polynucleotide is labeled.
- 262  
238. (Previously Presented) A polynucleotide according to claim 208 wherein said polynucleotide is labeled.
- 56  
239. (Previously Presented) A polynucleotide according to claim 209 wherein said polynucleotide is labeled.
- 108  
240. (Previously Presented) A polynucleotide according to claim 210 wherein said polynucleotide is labeled.
- 159  
241. (Previously Presented) A polynucleotide according to claim 211 wherein said polynucleotide is labeled.
- 211  
242. (Previously Presented) A polynucleotide according to claim 212 wherein said polynucleotide is labeled.
- 228  
243. (Previously Presented) A polynucleotide according to claim 213 wherein said polynucleotide is labeled.
- 22  
244. (Previously Presented) A polynucleotide according to claim 214 wherein said polynucleotide is labeled.

245. (Previously Presented) A polynucleotide according to claim 215 wherein said polynucleotide is labeled.
246. (Previously Presented) A polynucleotide according to claim 216 wherein said polynucleotide is labeled.
247. (Previously Presented) A polynucleotide according to claim 217 wherein said polynucleotide is labeled.
248. (Previously Presented) A polynucleotide according to claim 218 wherein said polynucleotide is labeled.
249. (Previously Presented) A polynucleotide according to claim 219 wherein said polynucleotide is labeled.
250. (Previously Presented) A polynucleotide according to claim 220 wherein said polynucleotide is labeled.
251. (Previously Presented) A polynucleotide according to claim 221 wherein said polynucleotide is labeled.
252. (Previously Presented) A polynucleotide according to any of claims 60-73 wherein said polynucleotide is an oligonucleotide.
253. (Previously Presented) A polynucleotide according to claim 74 wherein said polynucleotide is an oligonucleotide.
254. (Previously Presented) A polynucleotide according to claim 75 wherein said polynucleotide is an oligonucleotide.

- 166  
255. (Previously Presented) A polynucleotide according to claim 76 wherein said polynucleotide is an oligonucleotide.
- 218  
256. (Previously Presented) A polynucleotide according to claim 77 wherein said polynucleotide is an oligonucleotide.
- 235  
257. (Previously Presented) A polynucleotide according to claim 78 wherein said polynucleotide is an oligonucleotide.
- 29  
258. (Previously Presented) A polynucleotide according to claim 79 wherein said polynucleotide is an oligonucleotide.
- 82  
259. (Previously Presented) A polynucleotide according to claim 80 wherein said polynucleotide is an oligonucleotide.
- 133  
260. (Previously Presented) A polynucleotide according to claim 81 wherein said polynucleotide is an oligonucleotide.
- 154  
261. (Previously Presented) A polynucleotide according to claim 82 wherein said polynucleotide is an oligonucleotide.
- 253  
262. (Previously Presented) A polynucleotide according to claim 83 wherein said polynucleotide is an oligonucleotide.
- 47  
263. (Previously Presented) A polynucleotide according to claim 84 wherein said polynucleotide is an oligonucleotide.
264. 99 (Previously Presented) A polynucleotide according to claim 85 wherein said polynucleotide is an oligonucleotide.

- 150  
265. (Previously Presented) A polynucleotide according to claim 86 wherein said polynucleotide is an oligonucleotide.
- 202  
266. (Previously Presented) A polynucleotide according to claim 87 wherein said polynucleotide is an oligonucleotide.
- 194  
267. (Previously Presented) A polynucleotide according to claim 222 wherein said polynucleotide is labeled.
- 274  
268. (Previously Presented) An oligonucleotide according to claim 252 wherein said oligonucleotide is labeled.
- 64  
269. (Previously Presented) An oligonucleotide according to claim 253 wherein said oligonucleotide is labeled.
- 116  
270. (Previously Presented) An oligonucleotide according to claim 254 wherein said oligonucleotide is labeled.
- 167  
271. (Previously Presented) An oligonucleotide according to claim 255 wherein said oligonucleotide is labeled.
- 219  
272. (Previously Presented) An oligonucleotide according to claim 256 wherein said oligonucleotide is labeled.
- 234  
273. (Previously Presented) An oligonucleotide according to claim 257 wherein said oligonucleotide is labeled.
- 30  
274. (Previously Presented) An oligonucleotide according to claim 258 wherein said oligonucleotide is labeled.

- 83  
275. (Previously Presented) An oligonucleotide according to claim 259 wherein said oligonucleotide is labeled.
- 134 82  
276. (Previously Presented) An oligonucleotide according to claim 260 wherein said oligonucleotide is labeled.
- 185 133  
277. (Previously Presented) An oligonucleotide according to claim 261 wherein said oligonucleotide is labeled.
- 254 184  
278. (Previously Presented) An oligonucleotide according to claim 262 wherein said oligonucleotide is labeled.
- 48 253  
279. (Previously Presented) An oligonucleotide according to claim 263 wherein said oligonucleotide is labeled.
- 100 47  
280. (Previously Presented) An oligonucleotide according to claim 264 wherein said oligonucleotide is labeled.
- 151 99  
281. (Previously Presented) An oligonucleotide according to claim 265 wherein said oligonucleotide is labeled.
- 203 150  
282. (Previously Presented) An oligonucleotide according to claim 266 wherein said oligonucleotide is labeled.
- 195 202  
283. (Previously Presented) A polynucleotide according to claim 267 wherein said polynucleotide is an oligonucleotide.
- 277 194  
284. (Previously Presented) A composition comprising the polynucleotide of any of claims 60-73 wherein said polynucleotide is substantially isolated.
- 1-14



- 65  
285. (Previously Presented) A composition comprising the polynucleotide of claim 74 wherein said polynucleotide is substantially isolated.
- 117  
286. (Previously Presented) A composition comprising the polynucleotide of claim 75 wherein said polynucleotide is substantially isolated.
- 168  
287. (Previously Presented) A composition comprising the polynucleotide of claim 76 wherein said polynucleotide is substantially isolated.
- 220  
288. (Previously Presented) A composition comprising the polynucleotide of claim 77 wherein said polynucleotide is substantially isolated.
- 237  
289. (Previously Presented) A composition comprising the polynucleotide of claim 78 wherein said polynucleotide is substantially isolated.
- 31  
290. (Previously Presented) A composition comprising the polynucleotide of claim 79 wherein said polynucleotide is substantially isolated.
- 84  
291. (Previously Presented) A composition comprising the polynucleotide of claim 80 wherein said polynucleotide is substantially isolated.
- 135  
292. (Previously Presented) A composition comprising the polynucleotide of claim 81 wherein said polynucleotide is substantially isolated.
- 186  
293. (Previously Presented) A composition comprising the polynucleotide of claim 82 wherein said polynucleotide is substantially isolated.
- 255  
294. (Previously Presented) A composition comprising the polynucleotide of claim 83 wherein said polynucleotide is substantially isolated.

- 49  
295. (Previously Presented) A composition comprising the polynucleotide of claim <sup>33</sup>84 wherein said polynucleotide is substantially isolated.
- 101  
296. (Previously Presented) A composition comprising the polynucleotide of claim <sup>84</sup>85 wherein said polynucleotide is substantially isolated.
- 152  
297. (Previously Presented) A composition comprising the polynucleotide of claim <sup>137</sup>86 wherein said polynucleotide is substantially isolated.
- 204  
298. (Previously Presented) A composition comprising the polynucleotide of claim <sup>188</sup>87 wherein said polynucleotide is substantially isolated.
- 263  
299. (Previously Presented) A composition comprising the polynucleotide of claim <sup>257</sup>88 wherein said polynucleotide is substantially isolated.
- 57  
300. (Previously Presented) A composition comprising the polynucleotide of claim <sup>51</sup>89 wherein said polynucleotide is substantially isolated.
- 109  
301. (Previously Presented) A composition comprising the polynucleotide of claim <sup>103</sup>90 wherein said polynucleotide is substantially isolated.
- 160  
302. (Previously Presented) A composition comprising the polynucleotide of claim <sup>154</sup>91 wherein said polynucleotide is substantially isolated.
- 212  
303. (Previously Presented) A composition comprising the polynucleotide of claim <sup>206</sup>92 wherein said polynucleotide is substantially isolated.
- 229  
304. (Previously Presented) A composition comprising the polynucleotide of claim <sup>273</sup>93 wherein said polynucleotide is substantially isolated.

- 23  
305. (Previously Presented) A composition comprising the polynucleotide of claim 94 wherein said polynucleotide is substantially isolated.
- 75  
306. (Previously Presented) A composition comprising the polynucleotide of claim 95 wherein said polynucleotide is substantially isolated.
- 127  
307. (Previously Presented) A composition comprising the polynucleotide of claim 96 wherein said polynucleotide is substantially isolated.
- 
- 178  
308. (Previously Presented) A composition comprising the polynucleotide of claim 97 wherein said polynucleotide is substantially isolated.
- 246  
309. (Previously Presented) A composition comprising the polynucleotide of claim 98 wherein said polynucleotide is substantially isolated.
- 40  
310. (Previously Presented) A composition comprising the polynucleotide of claim 99 wherein said polynucleotide is substantially isolated.
- 93  
311. (Previously Presented) A composition comprising the polynucleotide of claim 100 wherein said polynucleotide is substantially isolated.
- 144  
312. (Previously Presented) A composition comprising the polynucleotide of claim 101 wherein said polynucleotide is substantially isolated.
- 196  
313. (Previously Presented) A composition comprising the polynucleotide of claim 102 wherein said polynucleotide is substantially isolated.
- 279  
314. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of any of claims 60-73 in a suitable package.

<sup>66</sup>  
315. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>15</sup>74 in a suitable package.

<sup>118</sup>  
316. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>67</sup>75 in a suitable package.

<sup>169</sup>  
317. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>159</sup>76 in a suitable package.

<sup>221</sup>  
318. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>70</sup>77 in a suitable package.

<sup>238</sup>  
319. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>222</sup>78 in a suitable package.

<sup>32</sup>  
320. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>16</sup>79 in a suitable package.

<sup>85</sup>  
321. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>68</sup>80 in a suitable package.

<sup>136</sup>  
322. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>120</sup>81 in a suitable package.

<sup>187</sup>  
323. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>171</sup>82 in a suitable package.

<sup>256</sup>  
324. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>239</sup>83 in a suitable package.

50  
325. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>33</sup>84 in a suitable package.

102  
326. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>56</sup>85 in a suitable package.

153  
327. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>137</sup>86 in a suitable package.

205  
328. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>128</sup>87 in a suitable package.

264  
329. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>257</sup>88 in a suitable package.

76  
330. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>69</sup>98 in a suitable package.

41  
331. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>34</sup>99 in a suitable package.

249  
332. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>247</sup>113 in a suitable package.

281  
→ 333. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>197</sup>117 in a suitable package.

268  
334. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>267</sup>133 in a suitable package.

- 272  
335. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>269</sup>193 in a suitable package.
- 271  
336. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>270</sup>223 in a suitable package.
- 276  
337. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>273</sup>252 in a suitable package.
- 278  
338. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>277</sup>284 in a suitable package.
- 275  
339. (Previously Presented) A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim <sup>274</sup>268 in a suitable package.
- 280  
340. (Previously Presented) A polynucleotide of any of claims <sup>1-14</sup>60-73 wherein said polynucleotide encodes a polypeptide having a sequence comprising at least 10 contiguous amino acids from an HCV1 polyprotein.
- 282  
341. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 3.
- 283  
342. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 62A.
- 284  
343. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a

detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 89.

285  
344. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

286  
345. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

287  
346. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 89.

288  
347. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 14.

289  
348. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of Figure 58.

292  
349. (Previously Presented) A method according to any of claims 285-289 wherein said selected samples comprise said polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said polynucleotide and said contiguous

sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

350. Canceled.

<sup>293</sup>  
351. (Previously Presented) A method according to claim <sup>292</sup>349 wherein said polynucleotide is detectable in a PCR assay.

<sup>300</sup>  
352. (Previously Presented) A method according to claim <sup>292</sup>349 wherein said biological samples are blood.

353. Canceled.

<sup>294</sup>  
354. (Previously Presented) A method according to claim <sup>293</sup>351 wherein said biological samples are blood.

<sup>304</sup>  
355. (Previously Presented) A method according to claim <sup>292</sup>349 wherein said biological samples are plasma.

356. Canceled.

<sup>296</sup>  
357. (Previously Presented) A method according to claim <sup>293</sup>351 wherein said biological samples are plasma.

~~307~~  
358. (Previously Presented) A method according to claim <sup>292</sup>349 wherein said biological samples are sera.

359. Canceled.

<sup>298</sup>  
360. (Previously Presented) A method according to claim <sup>293</sup>351 wherein said biological samples are sera.

<sup>301</sup>  
361. (Previously Presented) A method according to claim <sup>300</sup>352 further comprising employing biological samples that are not selected for a preparation of blood-related products.

<sup>305</sup>  
362. (Previously Presented) A method according to claim <sup>304</sup>355 further comprising employing biological samples that are not selected for a preparation of blood-related products.



<sup>302</sup>  
363. (Previously Presented) A method according to claim 352 further comprising preparing polyclonal antibodies with selected biological samples.

<sup>290</sup>  
364. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

<sup>291</sup>  
365. (Previously Presented) A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as A TCC No. 40394.

<sup>303</sup>  
366. (Previously Presented) A method according to claim <sup>300</sup>352 wherein the selecting is to identify an HCV positive sample for removal from the supply.

367. Canceled.

<sup>295</sup>  
368. (Previously Presented) A method according to claim <sup>294</sup>354 wherein the selecting is to identify an HCV positive sample for removal from the supply.

<sup>306</sup>  
369. (Previously Presented) A method according to claim <sup>304</sup>355 wherein the selecting is to identify an HCV positive sample for removal from the supply.

370. Canceled.

<sup>297</sup>  
371. (Previously Presented) A method according to claim <sup>296</sup>357 wherein the selecting is to identify an HCV positive sample for removal from the supply.

<sup>308</sup>  
372. (Previously Presented) A method according to claim <sup>307</sup>358 wherein the selecting is to identify an HCV positive sample for removal from the supply.

373. Canceled.

299  
374. (Previously Presented) A method according to claim 360 wherein the selecting is to identify an HCV positive sample for removal from the supply.

375. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

376. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

377. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as A TCC No. 40394.

378. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

379. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second

polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

~~380~~ 373

380. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

~~381~~ 344

381. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either strand of Figure 58.

~~382~~ 374

382. (Previously Presented) A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either stand of Figure 58.

~~383~~ 345

383. (Previously Presented) A method according to any of claims 375, 377, 379, 381 wherein said selected samples comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence of nucleotides and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

~~384~~ 375

384. (Previously Presented) A method according to any of claims 376, 378, 380, 382 wherein said selected samples do not comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

346  
385. (Previously Presented) A method according to claim ~~383~~<sup>345</sup>, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

~~384~~<sup>376</sup>  
386. (Previously Presented) A method according to claim ~~384~~<sup>379</sup>, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

~~387~~<sup>358</sup>  
387. (Previously Presented) A method according to claim ~~383~~<sup>345</sup> wherein said first polynucleotide is detectable in a PCR assay.

~~388~~<sup>347</sup>  
388. (Previously Presented) A method according to ~~385~~<sup>344</sup>, wherein said first polynucleotide is detectable in a PCR assay.

~~389~~<sup>398</sup>  
389. (Previously Presented) A method according to claim ~~384~~<sup>375</sup> wherein said first polynucleotide is not detectable in a PCR assay.

~~390~~<sup>377</sup>  
390. (Previously Presented) A method according to claim ~~386~~<sup>396</sup> wherein said first polynucleotide is not detectable in a PCR assay.

~~391~~<sup>401</sup>  
391. (Previously Presented) A method according to any of claims ~~375-382~~<sup>391-394 or 371-374</sup> wherein said biological samples are blood.

~~392~~<sup>379 364</sup>  
392. (Previously Presented) A method according to claim ~~383~~<sup>355-345</sup> wherein said biological samples are blood.

~~393~~<sup>414 394</sup>  
393. (Previously Presented) A method according to claim ~~384~~<sup>375 375</sup> wherein said biological samples are blood.

~~394~~<sup>363 353</sup>  
394. (Previously Presented) A method according to claim ~~385~~<sup>346</sup> wherein said biological samples are blood.

~~395~~<sup>383 383</sup>  
395. (Previously Presented) A method according to claim ~~386~~<sup>376 376</sup> wherein said biological samples are blood.

~~396~~<sup>359 359</sup>  
396. (Previously Presented) A method according to claim ~~387~~<sup>358 358</sup> wherein said biological samples are blood.

- 348  
~~348~~
397. (Previously Presented) A method according to claim ~~388~~ 347 wherein said biological samples are blood.
- ~~400~~ 389  
398. (Previously Presented) A method according to claim ~~389~~ 400 388 wherein said biological samples are blood.
- ~~398~~ 378  
399. (Previously Presented) A method according to claim ~~390~~ 377 wherein said biological samples are blood.
- 402  
400. (Previously Presented) A method according to any of claims ~~375-382~~ 341-344 or 371-374 wherein said biological samples are plasma.
- ~~375~~ 365  
401. (Previously Presented) A method according to claim ~~383~~ 345 wherein said biological samples are plasma.
- ~~405~~ 395  
402. (Previously Presented) A method according to claim ~~384~~ 375 wherein said biological samples are plasma.
- ~~384~~ 354  
403. (Previously Presented) A method according to claim ~~385~~ 346 wherein said biological samples are plasma.
- ~~404~~ 384  
404. (Previously Presented) A method according to claim ~~386~~ 374 wherein said biological samples are plasma.
- ~~390~~ 360  
405. (Previously Presented) A method according to claim ~~387~~ 358 wherein said biological samples are plasma.
- ~~387~~ 349  
406. (Previously Presented) A method according to claim ~~388~~ 347 wherein said biological samples are plasma.
- ~~407~~ 390  
407. (Previously Presented) A method according to claim ~~389~~ 388 wherein said biological samples are plasma.
- ~~389~~ 379  
408. (Previously Presented) A method according to claim ~~390~~ 377 wherein said biological samples are plasma.

- 403  
409. (Previously Presented) A method according to any of claims ~~375-382~~ wherein said biological samples are sera.
- 360 345  
410. (Previously Presented) A method according to claim ~~383~~ wherein said biological samples are sera.
- 396 375  
411. (Previously Presented) A method according to claim ~~384~~ wherein said biological samples are sera.
- 355 346  
412. (Previously Presented) A method according to claim ~~385~~ wherein said biological samples are sera.
- 385 376  
413. (Previously Presented) A method according to claim ~~386~~ wherein said biological samples are sera.
- 361 358  
414. (Previously Presented) A method according to claim ~~387~~ wherein said biological samples are sera.
- 350 347  
415. (Previously Presented) A method according to claim ~~388~~ wherein said biological samples are sera.
- 391 388  
416. (Previously Presented) A method according to claim ~~389~~ wherein said biological samples are sera.
- 380 377  
417. (Previously Presented) A method according to claim ~~390~~ wherein said biological samples are sera.
- 369 341-344  
418. (Previously Presented) A method according to any of claims ~~375, 377, 379 or 381~~ further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 367 345  
419. (Previously Presented) A method according to claim ~~383~~ further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 356 346  
420. (Previously Presented) A method according to claim ~~385~~ further comprising employing biological samples that are not selected for a preparation of blood-related products.

- 362  
421. (Previously Presented) A method according to claim 387 further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 351  
422. (Previously Presented) A method according to claim 388 further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 399  
423. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 further comprising employing biological samples that are selected for a preparation of blood-related products.
- 397  
424. (Previously Presented) A method according to claim 384 further comprising employing biological samples that are selected for a preparation of blood-related products.
- 386  
425. (Previously Presented) A method according to claim 386 further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 392  
426. (Previously Presented) A method according to claim 385 further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 391  
427. (Previously Presented) A method according to claim 390 further comprising employing biological samples that are not selected for a preparation of blood-related products.
- 400  
428. (Previously Presented) A method according to any of claims 376, 378, 380 or 382 wherein said selected samples are supply samples for preparation of blood products.
- 398  
429. (Previously Presented) A method according to claim 384 wherein said selected samples are supply sample for preparation of blood products.
- 387  
430. (Previously Presented) A method according to claim 386 wherein said selected samples are supply sample for preparation of blood products.
- 393  
431. (Previously Presented) A method according to claim 389 wherein said selected samples are supply sample for preparation of blood products.
- 395  
432. (Previously Presented) A method according to claim 390 wherein said selected samples are supply sample for preparation of blood products.

- 390  
433. (Previously Presented) A method according to any of claims ~~375, 377, 379 or 381~~<sup>351-354</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- 308  
434. (Previously Presented) A method according to claim ~~383~~<sup>355</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- 367  
435. (Previously Presented) A method according to claim ~~385~~<sup>356</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- 373  
436. (Previously Presented) A method according to claim ~~387~~<sup>368</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- 362  
437. (Previously Presented) A method according to claim ~~388~~<sup>357</sup> wherein said samples that are not selected are supply samples for preparation of blood products.

Please add the following new claims:

- 384  
438. (New) A method according to any of claims ~~341-348, 364 or 365~~<sup>282-291</sup> wherein said polynucleotide is detectable in a PCR assay.
- 385  
439. (New) A method according to claim ~~438~~<sup>334</sup> wherein said biological samples are blood.
- 387  
440. (New) A method according to claim ~~438~~<sup>334</sup> wherein said biological samples are plasma.
- 389  
441. (New) A method according to claim ~~438~~<sup>334</sup> wherein said biological samples are sera.
- 386  
442. (New) A method according to claim ~~439~~<sup>335</sup> wherein the selecting is to identify an HCV positive sample for removal from the supply.
- 388  
443. (New) A method according to claim ~~440~~<sup>337</sup> wherein the selecting is to identify an HCV positive sample for removal from the supply.



- 340  
444 (New) A method according to claim 441 wherein the selecting is to identify an HCV positive sample for removal from the supply.
- 322  
445. (New) A method according to claims 344-348, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.
- 310  
446. (New) A method according to claim 349 wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.
- 323  
447. (New) A method according to claim 445 wherein said polynucleotide is detectable in a PCR assay.
- 311  
448. (New) A method according to claim 446 wherein said polynucleotide is detectable in a PCR assay.
- 329  
449. (New) A method according to claim 445 wherein said biological samples are blood.
- 317  
450. (New) A method according to claim 446 wherein said biological samples are blood.
- 330  
451. (New) A method according to claim 445 wherein said biological samples are plasma.
- 318  
452. (New) A method according to claim 446 wherein said biological samples are plasma.
- 331  
453. (New) A method according to claim 445 wherein said biological samples are sera.
- 319  
454. (New) A method according to claim 446 wherein said biological samples are sera.
- 324  
455. (New) A method according to claim 447 wherein said biological samples are blood.
- 312  
456. (New) A method according to claim 448 wherein said biological samples are blood.
- 325  
457. (New) A method according to claim 447 wherein said biological samples are sera.
- 313  
458. (New) A method according to claim 448 wherein said biological samples are sera.
- 326  
459. (New) A method according to claim 447 wherein said biological samples are plasma.
- 314  
460. (New) A method according to claim 448 wherein said biological samples are plasma.

- <sup>332</sup>  
461. (New) A method according to claim ~~445~~<sup>322</sup> further comprising employing biological samples that are not selected for a preparation of blood-related products.
- <sup>320</sup>  
462. (New) A method according to claim ~~446~~<sup>310</sup> further comprising employing biological samples that are not selected for a preparation of blood-related products.
- <sup>327</sup>  
463. (New) A method according to claim ~~447~~<sup>323</sup> further comprising employing biological samples that are not selected for a preparation of blood-related products.
- <sup>315</sup>  
464. (New) A method according to claim ~~448~~<sup>311</sup> further comprising employing biological samples that are not selected for a preparation of blood-related products.
- <sup>333</sup>  
465. (New) A method according to claim ~~445~~<sup>322</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- <sup>321</sup>  
466. (New) A method according to claim ~~446~~<sup>310</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- <sup>328</sup>  
467. (New) A method according to claim ~~447~~<sup>323</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- <sup>316</sup>  
468. (New) A method according to claim ~~448~~<sup>311</sup> wherein said samples that are not selected are supply samples for preparation of blood products.
- <sup>309</sup>  
469. (New) A method according to claim ~~358~~<sup>307</sup> further comprising employing biological samples that are not selected for a preparation of blood-related products.